NCT00798174

Brief Summary

When implantable cardiac defibrillators are implanted (ICDs), the defibrillation threshold (DFT), of the amount of energy required to effectively terminate life-threatening arrhythmias is determined. The device is then programmed to discharge a larger amount of energy in order to provide a safety margin. In some patients, the DFT is so high, that an adequate safety margin is not programmable. Placement of a defibrillation lead in the azygos vein has been found to be helpful in these patients. This goal of this trial is to attempt to quantify the average reduction in the DFT (if any) that results from the addition of the azygos lead.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Dec 2008

Shorter than P25 for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 24, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 26, 2008

Completed
19 days until next milestone

Study Start

First participant enrolled

December 15, 2008

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 18, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 18, 2009

Completed
8.9 years until next milestone

Results Posted

Study results publicly available

September 28, 2018

Completed
Last Updated

September 28, 2018

Status Verified

August 1, 2018

Enrollment Period

11 months

First QC Date

November 24, 2008

Results QC Date

February 1, 2018

Last Update Submit

August 27, 2018

Conditions

Keywords

DFTCongestive Heart failure (CHF)ICD

Outcome Measures

Primary Outcomes (1)

  • Difference in the DFT With an Azygos Vein Coil Versus the Standard SVC Coil.

    Defibrillation threshold will be estimated by repeat defibrillation testing using an azygos coil and using an SVC coil (and compared). The outcome measure quoted below is the mean DFT using the azygos coil vs. the mean DFT using the standard configuration.

    During the course of the implant procedure and testing

Study Arms (1)

Standard configuration vs. azygos coil

EXPERIMENTAL

The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil. In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil

Device: Standard configuration vs. azygos coil

Interventions

Addition of an azygos vein defibrillation coil instead of a standard SVC coil.

Also known as: Medtronic 6937A Lead
Standard configuration vs. azygos coil

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Any contraindication to ICD or the inability to place an azygos vein coil.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Washington University

St Louis, Missouri, 63110, United States

Location

Related Publications (2)

  • Cooper JA, Latacha MP, Soto GE, Garmany RG, Gleva MJ, Chen J, Faddis MN, Smith TW. The azygos defibrillator lead for elevated defibrillation thresholds: implant technique, lead stability, and patient series. Pacing Clin Electrophysiol. 2008 Nov;31(11):1405-10. doi: 10.1111/j.1540-8159.2008.01203.x.

    PMID: 18950297BACKGROUND
  • Cesario D, Bhargava M, Valderrabano M, Fonarow GC, Wilkoff B, Shivkumar K. Azygos vein lead implantation: a novel adjunctive technique for implantable cardioverter defibrillator placement. J Cardiovasc Electrophysiol. 2004 Jul;15(7):780-3. doi: 10.1046/j.1540-8167.2004.03649.x.

    PMID: 15250862BACKGROUND

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Results Point of Contact

Title
Dr. Timothy W. Smith
Organization
Washington University in St. Louis

Study Officials

  • Timothy W. Smith, DPhil, MD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Single group undergoing crossover in therapy (defibrillation testing with two different device configurations).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2008

First Posted

November 26, 2008

Study Start

December 15, 2008

Primary Completion

November 18, 2009

Study Completion

November 18, 2009

Last Updated

September 28, 2018

Results First Posted

September 28, 2018

Record last verified: 2018-08

Locations